ECSP12011689A - Combinación de un agente quimioterapéutico y un inhibidor del sistema tgf-beta - Google Patents

Combinación de un agente quimioterapéutico y un inhibidor del sistema tgf-beta

Info

Publication number
ECSP12011689A
ECSP12011689A ECSP12011689A ECSP12011689A EC SP12011689 A ECSP12011689 A EC SP12011689A EC SP12011689 A ECSP12011689 A EC SP12011689A EC SP12011689 A ECSP12011689 A EC SP12011689A
Authority
EC
Ecuador
Prior art keywords
chemotherapeutic agent
tgf
inhibitor
combination
antisense oligonucleotide
Prior art date
Application number
Other languages
English (en)
Inventor
Karl Hermann Schlingensiepen
Frank Jaschinski
Tanja Rothammer
Anneliese Schneider
Original Assignee
Antisense Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41278403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12011689(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Antisense Pharma Gmbh filed Critical Antisense Pharma Gmbh
Publication of ECSP12011689A publication Critical patent/ECSP12011689A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Composición farmacéutica que comprende un agente quimioterapéutico y un oligonucleótido antisentido contra TGF-beta, donde el oligonucleótido antisentido reduce la sensibilidad y la IC50, respectivamente, de la citotoxicidad del agente quimioterapéutico. De preferencia, el oligonucleótido antisentido es un oligonucleótido antisentido contra TGF-beta 1, 2 y/o 3 y el agente quimioterapéutico de preferencia es gemcitabina, 5-fluorouracilo, temozolomida, dacarbacina, docetaxel, cisplatino, oxaliplatino, tamoxifeno o irinotecán.
ECSP12011689 2009-07-30 2012-02-23 Combinación de un agente quimioterapéutico y un inhibidor del sistema tgf-beta ECSP12011689A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09166893 2009-07-30

Publications (1)

Publication Number Publication Date
ECSP12011689A true ECSP12011689A (es) 2012-06-29

Family

ID=41278403

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011689 ECSP12011689A (es) 2009-07-30 2012-02-23 Combinación de un agente quimioterapéutico y un inhibidor del sistema tgf-beta

Country Status (17)

Country Link
US (1) US8476246B2 (es)
EP (1) EP2340308B1 (es)
JP (1) JP2013500313A (es)
KR (1) KR20120107456A (es)
CN (1) CN102712924A (es)
AU (1) AU2010277554B2 (es)
BR (1) BR112012002102A2 (es)
CA (1) CA2769618A1 (es)
CL (1) CL2012000247A1 (es)
CO (1) CO6511199A2 (es)
EC (1) ECSP12011689A (es)
IL (1) IL217821A0 (es)
IN (1) IN2012DN00969A (es)
MX (1) MX2012001244A (es)
PE (1) PE20121495A1 (es)
RU (1) RU2012107535A (es)
WO (1) WO2011012713A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1465995B1 (en) * 2002-01-17 2008-07-30 The University of British Columbia Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
CN103517990A (zh) 2010-10-07 2014-01-15 通用医疗公司 癌症生物标志物
TWI454281B (zh) * 2011-10-06 2014-10-01 Nat Univ Tsing Hua 硼酸於硼中子捕獲治療肝癌之用途
WO2013124869A2 (en) * 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University The art, method,manner process and system of fibrous bio-degradable polymeric wafers for the local delivery of therapeutic agents in combinations
CA2903239A1 (en) * 2013-03-14 2014-10-02 Oncogenex Technologies Inc. Custirsen treatment with reduced toxicity
US10386359B2 (en) * 2014-05-23 2019-08-20 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for determining whether a patient will achieve a response after radiation therapy
EP3760208B1 (en) 2014-06-25 2024-05-29 The General Hospital Corporation Targeting human satellite ii (hsatii)
WO2016081503A1 (en) * 2014-11-17 2016-05-26 City Of Hope Tki permeability enhancers
CA2990852A1 (en) 2015-06-26 2016-12-29 Beth Israel Deaconess Medical Center, Inc. Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
WO2017138925A1 (en) 2016-02-09 2017-08-17 Autotelic Llc Antitumour combinations of antisense oligonucleotides and anticancer agents
KR20180103816A (ko) 2016-02-09 2018-09-19 오토텔릭 엘엘씨 췌장암을 치료하기 위한 조성물과 방법
US9758786B2 (en) * 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
CA3037046A1 (en) 2016-10-31 2018-05-03 University Of Massachusetts Targeting microrna-101-3p in cancer therapy
WO2018089688A1 (en) 2016-11-09 2018-05-17 Jinjun Shi Restoration of tumor suppression using mrna-based delivery system
US20210213041A1 (en) 2018-02-06 2021-07-15 The General Hospital Corporation Repeat rna as biomarkers of tumor immune response
KR20210139237A (ko) * 2019-03-14 2021-11-22 더 리서치 파운데이션 포 더 스테이트 유니버시티 오브 뉴욕 변형된 마이크로rna 및 암 치료에 있어서의 이의 용도
GB201908012D0 (en) * 2019-06-05 2019-07-17 Io Biotech Aps TGF-Beta vaccine
CN112933238A (zh) * 2021-02-02 2021-06-11 石河子大学 抑制TGF-βR1基因表达的物质与顺铂在治疗和/或预防食管癌中的应用
CN113425855B (zh) * 2021-06-28 2023-11-07 深圳瑞吉生物科技有限公司 一种mRNA剂型的骨关节炎药物制剂及其制备方法和应用
WO2025193774A1 (en) * 2024-03-12 2025-09-18 The Regents Of The University Of California Methods of identifying and treating an immune poor cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
WO1983001451A1 (en) 1981-10-23 1983-04-28 Molecular Biosystems Inc Oligonucleotide therapeutic agent and methods of making same
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
EP0856579A1 (en) * 1997-01-31 1998-08-05 BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH An antisense oligonucleotide preparation method
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US6809118B2 (en) * 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
CN1845733A (zh) * 2003-09-04 2006-10-11 学校法人日本大学 TGF－β基因表达抑制剂
ZA200602941B (en) * 2003-11-13 2007-07-25 Genentech Inc Screening assays and methods of tumor treatment
KR20060127409A (ko) * 2003-11-13 2006-12-12 제넨테크, 인크. 종양 치료 방법 및 스크리닝 검정
WO2005059133A2 (en) 2003-12-19 2005-06-30 Antisense Pharma Gmbh Combination therapy associating a tgf-breta antagonist with a chemiotherapeutic agent
US20070155685A1 (en) * 2004-02-27 2007-07-05 Karl-Hermann Schlingensiepen Pharmaceutical composition
US20090186076A1 (en) * 2006-02-01 2009-07-23 Kazunori Kataoka Combined Use of TGF-Beta Signaling Inhibitor and Antitumor Agent
JP5322476B2 (ja) * 2008-03-31 2013-10-23 テルモ株式会社 リポソームの製造装置およびリポソームの製造方法

Also Published As

Publication number Publication date
WO2011012713A1 (en) 2011-02-03
IL217821A0 (en) 2012-03-29
IN2012DN00969A (es) 2015-04-10
PE20121495A1 (es) 2012-11-19
KR20120107456A (ko) 2012-10-02
CN102712924A (zh) 2012-10-03
CL2012000247A1 (es) 2013-07-05
US20120027873A1 (en) 2012-02-02
MX2012001244A (es) 2012-03-26
AU2010277554B2 (en) 2015-02-19
AU2010277554A1 (en) 2012-03-01
EP2340308B1 (en) 2014-12-24
CA2769618A1 (en) 2011-02-03
US8476246B2 (en) 2013-07-02
EP2340308A1 (en) 2011-07-06
BR112012002102A2 (pt) 2017-05-02
CO6511199A2 (es) 2012-08-31
RU2012107535A (ru) 2013-09-10
JP2013500313A (ja) 2013-01-07

Similar Documents

Publication Publication Date Title
CO6511199A2 (es) Combinación de un agente quimioterapéutico y un inhibidor del sistema tgf- beta
UA105390C2 (ru) МОТИВЫ ХИМИЧЕСКИХ МОДИФИКАЦИЙ ДЛЯ ИНГИБИТОРОВ И МИМЕТИКОВ мкРНК
EA201070421A1 (ru) Микрорибонуклеиновые кислоты
CR10748A (es) Compuesto de indol
CL2013000423A1 (es) Forma de dosificacion farmaceutica con resistencia a rompimiento de al menos 500 n, que contiene un ingrediente activo, un polisacarido anionico y un oxido de polialquileno, en donde el ingrediente activo esta presente en una matriz de liberacion controlada comprendiendo el polisacarido anionico y el oxido de polialquileno.
BRPI0814874A2 (pt) combinação de agente antimitótico e inibidor da aurora quinase como tratamento anticâncer.
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
MX2015010083A (es) Nanoparticulas biodegradables y clinicamente compatibles como portadores para administracion de farmacos.
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
CL2007003495A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de la actividad de la akt; composicion farmaceutica; y uso para el tratamiento o prevencion del cancer.
CL2015002145A1 (es) Preparación, usos y formas sólidas de ácido obeticólico (divisional de solicitud n° 3475-2014)
CL2008000188A1 (es) Agente para suprimir la reaccion de rechazo cronica que comprende como ingrediente activo un inhibidor de il-6; y uso del inhibidor de il-6.
CL2017002682A1 (es) Forma de dosificación resistente a alteraciones con liberación inmediata y resistencia contra la extracción por solventes
DOP2011000386A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
CU24349B1 (es) Composiciones que comprenden 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas útiles para el tratamiento del cáncer
NO20091955L (no) Antivirale sammensetninger, og fremgangsmater for anvendelse
TR201818825T4 (tr) Kardi̇yak hi̇pertrofi̇ni̇n tedavi̇si̇ne ve tanisina yöneli̇k lncrnalar
MX2017004318A (es) Composiciones y metodos para el tratamiento y profilaxis de infecciones del sitio quirurgico.
TR201010683A1 (tr) Vildagliptin formülasyonları.
ECSP11011101A (es) Compuestos cicloundecadepsipéptidos y el uso de dichos compuestos como un medicamento
CL2007001514A1 (es) Compuestos derivados de triazina o diazina sustituida por cromano u isocromano, inhibidores de hsp90; composicion farmaceutica que comprende; y su uso en el tratamiento del cancer.
AR084487A1 (es) Componente prostesico con una superficie deslizante que contiene un recubrimiento antimicrobiano
CL2009002167A1 (es) Formulacion farmaceutica para administracion endovenosa que comprende un compuesto derivado de conjugados de camptotecina-polimero biocompatibles y biodegradables, un agente de estabilizacion, uno o varios tampones y un tensoactivo, util para el tratamiento del cancer.
ECSP11010856A (es) Composición farmacéutica sólida
CL2008000092A1 (es) Compuestos derivados de 3-cianopiridina, inhibidores del receptor p2y12; composicion farmaceutica que comprende a dichos compustos; y su uso en el tratamiento del transtorno de la agregacion plaquetaria.